New Set of Negotiated Medicare Drug Prices to Provide Real Relief to Consumers Paving a Proven Path to Further Lower Health Care Costs - Families USA Skip to Main Content
11.26.2025 / Statement

New Set of Negotiated Medicare Drug Prices to Provide Real Relief to Consumers Paving a Proven Path to Further Lower Health Care Costs

WASHINGTON, D.C. – Anthony Wright, Families USA’s executive director, issued the following statement today on the Centers for Medicare & Medicaid Services’ announcement of the second round of Medicare’s negotiated drug prices:

“This second announcement of negotiated drug prices shows what is possible when policymakers put patients before corporate profits and hold big drug companies accountable. These newly lowered prices build on the historic work that Congress and the Biden administration did to launch the Medicare Drug Price Negotiation Program to provide significant relief to older adults and people with disabilities. We are heartened to see the Trump administration continue this essential work on prescription drug prices. As millions of Americans are calling for relief from high health care costs, this announcement shows how politicians of both parties can use the purchasing power of public programs to actually address the affordability needs of families.

“Now, people with diabetes, cancer, asthma, heart disease and other serious chronic conditions have more affordable access to 15 more drugs to help them stay healthy. Together with the ten drugs Medicare negotiated for in 2024, price-negotiated prescriptions represent roughly one-third of Medicare Part D spending, underscoring how many Americans will benefit from this week’s announcement when these prices go into effect in 2027. The newly negotiated prices range from 38% to 85% lower than what Medicare previously paid. In 2027, people who rely on these drugs are projected to save $685 million in out-of-pocket costs. These negotiated prices help not just the individual patient with their out-of-pocket costs, but also the sustainability of Medicare as a whole, benefiting millions more taxpayers and beneficiaries broadly.

“While the vote to pass Medicare Drug Price negotiation as part of the inflation Reduction Act was on party lines, this new policy is wildly popular with Americans across the political spectrum. Despite ongoing attempts from big drug companies to roll back progress through a barrage of frivolous lawsuits and H.R. 1 provisions that undermine the program by exempting certain blockbuster drugs from negotiation, this program remains the most effective tool currently available to lower drug prices. Americans want meaningful action to lower health care costs, not empty promises and backroom deals. This announcement should remind us all that lasting change is possible when policymakers stand up to corporate power on behalf of families. Families USA urges Congress to build on this progress by expanding Medicare’s authority to negotiate more drugs for more people, so more Americans can benefit from fair, affordable prices.”